SWOG Institutional Grant

SWOG 机构补助金

• 批准号: 7116842
• 负责人: VERNON K. SONDAK
• 金额: $ 22.09万
• 依托单位: H. LEE MOFFITT CANCER CTR & RES INST
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-06-16 至 2006-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7116842
• 关键词: antineoplastics; biological response modifiers; bone marrow transplantation; brain neoplasms; breast neoplasms; cancer prevention; clinical research; clinical trials; combination cancer therapy; combination chemotherapy; cooperative study; ethnic group; fluorescent in situ hybridization; gastrointestinal neoplasms; gene therapy; head /neck neoplasm; health behavior; human subject; human therapy evaluation; leukemia; lymphoma; medical outreach /case finding; melanoma; multiple myeloma; neoplasm /cancer chemotherapy; neoplasm /cancer genetics; neoplasm /cancer immunotherapy; neoplasm /cancer pharmacology; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; neoplasm /cancer vaccine; nucleic acid sequence; pathologic process; patient oriented research; prognosis; reproductive system neoplasm; thorax neoplasm; tissue resource /registry; urinary tract neoplasms

DESCRIPTION (provided by applicant): The H. Lee Moffitt Cancer Center is uniquely positioned and prepared to pursue its mission of curing and preventing cancer. Founded by the Florida Legislature in the 1980's to become a statewide research institute and a national resource for basic and clinical research and multidisciplinary approach to patient treatment, the H. Lee Moffitt Cancer Center is the only NCI designated Comprehensive Cancer Center based in the state of Florida. The patient base is broad. The scientific leadership is growing with 81 investigators in ECOG, many of whom are doing investigator-initiated trials at Moffitt. The Cancer Center's commitment to ECOG is strong. Starting as an affiliate in 1992 under Dr. John Ruckdeschel, it soon achieved main member status and then received its own U-10 funding. Dr. William Dalton has become the new CEO of H. Lee Moffitt Cancer Center. He has a deep commitment to the cooperative group mechanism as an outlet for investigator initiated trials. The Cancer Center functions through 14 multidisciplinary programs. Each program leader has been charged by Dr. Dalton to develop a strategic plan which includes clinical trials at all levels of disease. This should enhance accrual to clinical trials. The ECOG program which includes the Principal Investigator, Julie A. Kish, MD, Coordinator, Stephanie Daniels, RN, Data Manager, Michele Stungis, and a 0.5 secretarial position, has become a model for clinical trial conduct for the institution. This extended to Moffitt's large affiliate network, where ECOG policies and procedures guide credentialing, monitoring and education. A major initiative to increase accrual of minorities to clinical trials has been instituted by Dr. Dalton called the Taskforce for Addressing Diversity (TAD). Thus, the goals of the ECOG Program at H. Lee Moffitt Cancer Center are to increase overall and minority accrual, and educate and mentor investigators to utilize the cooperative group for their investigator-initiated trials.

描述(由申请人提供)：H.Lee Moffitt癌症中心具有独特的定位和准备，以实现其治疗和预防癌症的使命。H.Lee Moffitt癌症中心由佛罗里达州议会于20世纪80年代由S创建，成为全州范围的研究机构和基础和临床研究以及多学科患者治疗方法的全国性资源，是美国国家癌症研究所唯一指定的位于佛罗里达州的综合癌症中心。患者基础广泛。科学领导地位正在增长，ECOG有81名研究人员，其中许多人在莫菲特进行由研究人员发起的试验。癌症中心对ECOG的承诺是坚定的。从1992年约翰·拉克德谢尔博士领导下的附属机构开始，它很快就获得了主要成员地位，然后获得了自己的U-10资金。威廉·道尔顿博士成为H·李·莫菲特癌症中心的新任首席执行官。他坚定地致力于合作小组机制，将其作为调查员发起的试验的渠道。癌症中心通过14个多学科项目发挥作用。道尔顿博士要求每个项目负责人制定一项战略计划，其中包括所有级别疾病的临床试验。这应该会增加临床试验的收益。ECOG项目包括首席研究员Julie A.Kish医学博士协调员Stephanie Daniels RN数据经理Michele Stungis和0.5个秘书职位，已成为该机构进行临床试验的典范。这延伸到了莫菲特的大型附属网络，在那里，经社理事会的政策和程序指导认证、监测和教育。道尔顿博士发起了一项名为解决多样性问题特别工作组(TAD)的重大倡议，旨在增加少数族裔参与临床试验的收益。因此，H.Lee Moffitt癌症中心ECOG计划的目标是增加总体和少数收益，并教育和指导研究人员在他们的研究人员发起的试验中利用合作小组。